Published in J Clin Oncol on January 25, 2016
The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol (2017) 1.04
The cost and value of cancer drugs - are new innovations outpacing our ability to pay? Isr J Health Policy Res (2016) 0.79
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst (2017) 0.78
Out-of-pocket costs and burden among rural breast cancer survivors. Cancer Med (2017) 0.75
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity. Cancer (2016) 0.75
Low-value practices in oncology contributing to financial toxicity. Ecancermedicalscience (2017) 0.75
Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status? J Oncol Pract (2016) 0.75
A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients? Oncologist (2016) 0.75
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics (2017) 0.75
With Colorectal Cancer Treatment, Physical Toxicity Is Not the Only Concern. Dis Colon Rectum (2018) 0.75
Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. J Clin Oncol (2017) 0.75
Bankruptcy linked to early mortality in patients with cancer. CA Cancer J Clin (2016) 0.75
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 13.63
Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin (2004) 12.55
Cumulative impact of sustained economic hardship on physical, cognitive, psychological, and social functioning. N Engl J Med (1997) 5.35
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist (2013) 4.33
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol (2013) 3.70
Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) (2013) 3.69
The impact of socioeconomic status on survival after cancer in the United States : findings from the National Program of Cancer Registries Patterns of Care Study. Cancer (2008) 3.13
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol (2012) 2.72
Full disclosure--out-of-pocket costs as side effects. N Engl J Med (2013) 1.90
Propensity score matching with time-dependent covariates. Biometrics (2005) 1.89
Self-reported economic difficulties and coronary events in men: evidence from the Whitehall II study. Int J Epidemiol (2005) 1.43
Changes in survival by ethnicity of patients with cancer between 1992-1996 and 2002-2006: is the discrepancy decreasing? Ann Oncol (2012) 1.30
Is cumulative exposure to economic hardships more hazardous to women's health than men's? A 16-year follow-up study of the Swedish Survey of Living Conditions. J Epidemiol Community Health (2007) 1.10
Financial strain predicts recurrent events among women with coronary artery disease. Int J Cardiol (2008) 1.07
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst (2014) 1.01
Financial hardship and mortality among older adults using the 1996-2004 Health and Retirement Study. Ann Epidemiol (2009) 0.97
Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm (2014) 0.87